Immuno-oncology, Insiders, Market, R&D

Who are the top 10 players that dominate the cancer drug market? And who’s growing fastest?

Severin Schwan, CEO Roche, speaks during a February 2017 press conference in Basel, Switzerland AP Images

The stellar sales performance of new immunotherapy drugs is driving a boom in investment dollars flowing into the field. And it's not hard to see why. Immunotherapy is delivering more sales, earlier exits, and higher returns on investment for biotech investors.

Last year, immuno-oncology drugs snagged 33% of all dollars spent on cancer drugs. That’s despite the fact that these therapies only make up 9% of all FDA-approved oncology drugs. These numbers underscore a simple fact in biopharma: If you're a major player in the cancer market, or want to become one, targeting immuno-oncology has become one of the favorite strategies for growing sales — quickly.

In this special report, we decided to give you all an overview of the biggest players in the cancer area, including their successes, what's top of mind in I/O, and the challenges that lie ahead for the top 10 companies. Includes charts and a table of select late-stage immuno-oncology therapies.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 21,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing